GSK•benzinga•May 13, 2025 at 11:58 AM

iTeos Reports Topline Interim Results From GALAXIES Lung-201 Study Of Belrestotug + Dostarlimab In First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients; Did Not Meet Established Criteria For Clinically Meaningful Improvements In Progression Free Sur

No summary available.

Read the full article from the original source for complete details and context.

Article published on May 13, 2025 by benzinga